Abstract:Background: The GABRA1 gene, encoding the GABR A R subunit α1, plays vital roles in inhibitory neurons. Previously, the GABRA1 gene has been identified to be associated with developmental and epileptic encephalopathy (DEE) and idiopathic generalized epilepsy (IGE). This study aims to explore the phenotypic spectrum of GABRA1 and molecular subregional effect analysis. Methods: Trios-based whole-exome sequencing was performed in patients with epilepsy. Previously reported GABRA1 mutations were systematically reviewed to analyze the molecular subregional effects. Results: De novo GABRA1 mutations were identified in six unrelated patients with heterogeneous epilepsy, including three missense mutations (p.His83Asn, p.Val207Phe, and p.Arg214Cys) and one frameshift mutation (p.Thr453Hisfs*47). The two missense mutations, p.His83Asn and p.Val207Phe, were predicted to decrease the protein stability but no hydrogen bond alteration, with which the two patients also presented with mild genetic epilepsy with febrile seizures plus and achieved seizure-free status by monotherapy. The missense variant p.Arg214Cys was predicted to decrease protein stability and destroy hydrogen bonds with surrounding residues, which was recurrently identified in three cases with severe DEE. The frameshift variant p.Thr453Hisfs*47 was located in the last fifth residue of the C-terminus and caused an extension of 47 amino acids, with which the patients presented with moderated epilepsy with generalized tonic-clonic seizures alone (GTCA) but achieved seizure-free status by four drugs. The four variants were not presented in gnomAD and were evaluated as "pathogenic/likely pathogenic" according to ACMG criteria. Analysis of all reported cases indicated that patients with mutations in the N-terminal extracellular region presented a significantly higher percentage of FS and DEE, and the patients with variants in the transmembrane region presented earlier seizure onset ages. Significance: This study suggested that GABRA1 variants were potentially associated with a spectrum of epilepsies, including EFS+, DEE, and GTCA. Phenotypic severity may be associated with the damaging effect of variants. The molecular subregional effects help in understanding the underlying mechanism of phenotypic variation.

ALG13-Related Epilepsy: Current Insights and Future Research Directions

ALG13 Participates in Epileptogenesis Via Regulation of GABA A Receptors in Mouse Models.

GABAA receptor epilepsy mutations

ALG13 Deficiency Associated with Increased Seizure Susceptibility and Severity.

CRISPR/Cas9-mediated mutation of asparagine-linked glycosylation 13 transcript variant 1 causes epilepsy in mice

The phenotypic spectrum of X-linked, infantile onset ALG13-related developmental and epileptic encephalopathy

ALG13 X‐linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypes

A conserved role for ALG10/ALG10B and the N-glycosylation pathway in the sleep-epilepsy axis

Clinical features of 4 patients with ALG13 gene related congenital disorders of glycosylation type Ⅰ

Interneuron FGF13 regulates seizure susceptibility via a sodium channel-independent mechanism

DLG3 variants caused X-linked epilepsy with/without neurodevelopmental disorders and the genotype-phenotype correlation

Impaired Brain Development in ALG13 Knockout Mice: Behavioral and Molecular Evidence

Impairments of GABAergic Transmission in Hippocampus Mediate Increased Susceptibility of Epilepsy in the Early Stage of Alzheimer’s Disease

Advance in Molecular Genetic Research on Generalized Epilepsies

Gene Variations of Glutamate Metabolism Pathway and Epilepsy

Long-term outcomes in ALG13-Congenital Disorder of Glycosylation

UNC13B variants associated with partial epilepsy with favourable outcome

Genetic and epigenetic mechanisms of epilepsy: a review

Similarity of Phenotype in Three Male Patients With the c.320A>G Variant in ALG13: Possible Genotype-Phenotype Correlation

Impairments of GABAergic transmission in hippocampus mediate increased susceptibility of epilepsy in the early stage of Alzheimer's disease

De novo GABRA1 variants in childhood epilepsies and the molecular subregional effects